New hope for liver cancer: drug combo targets tough cases
Disease control
Recruiting now
This study tests a new drug, WGI-0301, combined with sorafenib in 60 adults with advanced liver cancer that cannot be removed by surgery and has not responded to prior immunotherapy. The goal is to find the best dose and see if the combination can shrink tumors. Participants must…
Phase: PHASE2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC